The First Synthetic Oxytocin
| Category | Research |
|---|---|
| Also known as | synthetic oxytocin 1953, Pitocin history, du Vigneaud oxytocin synthesis |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | historyoxytocinpeptide-synthesisdu-vigneaud |
Overview
The first total synthesis of oxytocin was reported in 1953 by Vincent du Vigneaud and colleagues at Cornell University Medical College. Within a few years, synthetic oxytocin had replaced animal-derived pituitary extracts in obstetric practice and became the prototype for the wider introduction of synthetic peptide hormones into medicine.
Before 1953, oxytocin was administered in the form of posterior pituitary extracts (Pituitrin, pituitary snuff, and similar preparations) that contained a variable mixture of oxytocin, vasopressin, and other substances. These extracts were clinically useful but inconsistent, and their dual uterotonic and vasopressor activities made dose titration difficult. A pure, standardized oxytocin preparation — ideally one not derived from cadaveric or animal sources — was long desired.
Du Vigneaud's synthesis solved this problem. Within a few years, pharmaceutical companies were producing synthetic oxytocin (for example, Pitocin from Parke-Davis and Syntocinon from Sandoz) for induction and augmentation of labor and for postpartum hemorrhage. The synthetic product was chemically identical to natural oxytocin, with no vasopressin contamination and with defined, reproducible potency.
Key People
- Vincent du Vigneaud (1901–1978): Led the synthesis effort.
- Charles Ressler, John M. Roeske: Co-authors on the synthesis paper.
- Oliver Kamm: Earlier chemist who had separated oxytocin and vasopressin activities from pituitary extract.
- Henry H. Dale: British pharmacologist who established oxytocin's uterotonic activity in 1906.
Timeline
- 1906: Dale describes oxytocic activity of pituitary extracts.
- 1928: Kamm separates oxytocin and vasopressin from posterior pituitary extract.
- 1950: Du Vigneaud's group proposes the nonapeptide structure.
- 1953: Total synthesis published.
- 1955: Nobel Prize in Chemistry awarded to du Vigneaud.
- Mid-1950s: Synthetic oxytocin enters clinical use for labor induction and postpartum hemorrhage.
Background
Oxytocin's structure — a nine-amino-acid peptide with an internal disulfide bridge forming a six-amino-acid ring — made it a suitable but non-trivial synthetic target. Du Vigneaud's approach used carbobenzoxy protecting groups and mixed-anhydride couplings, with controlled oxidation to form the disulfide bridge. The resulting synthetic material showed identical biological activity and chromatographic behavior to purified natural oxytocin.
Clinical adoption was rapid. Pure synthetic oxytocin addressed the variability of pituitary extracts and eliminated the risk of vasopressor side effects. It also opened the door to systematic analog development. Within a decade, vasopressin had also been synthesized, and structure-activity studies comparing oxytocin and vasopressin analogs became a lively field of peptide chemistry.
Modern Relevance
Synthetic oxytocin remains among the most widely used peptide drugs in obstetric practice. It is standard therapy for the induction and augmentation of labor, prevention and treatment of postpartum hemorrhage, and certain other indications. Carbetocin, a longer-acting synthetic oxytocin analog, is used for prevention of postpartum hemorrhage in many countries.
Beyond obstetrics, oxytocin is widely studied as a modulator of social behavior, pair bonding, stress responses, and autism spectrum conditions. Intranasal oxytocin has been used in many human behavioral neuroscience studies, although clinical translation for behavioral indications remains an area of active debate. All of this research depends on the availability of pure synthetic peptide. See du-vigneaud-oxytocin for the discovery context.
Related Compounds
Related entries
- Du Vigneaud and the Synthesis of Oxytocin— In 1953, Vincent du Vigneaud synthesized oxytocin, the first biologically active peptide hormone made entirely in the laboratory.
- The First Peptide Drug— The first peptide drug is generally considered to be animal-derived insulin, introduced in 1923, followed by synthetic peptide hormones in the 1950s and 1960s.
- The 1955 Nobel Prize for Oxytocin Synthesis— The 1955 Nobel Prize in Chemistry went to Vincent du Vigneaud for his work on sulfur-containing biomolecules and the first synthesis of a peptide hormone, oxytocin.